Osteoporosis vaccine as well as preparation method and application thereof

By designing an osteoporosis vaccine containing diphtheria toxin transmembrane domain and hRANKL peptide, the side effects and high cost of existing osteoporosis treatment drugs have been solved, and long-term, mild and economical osteoporosis has been achieved. Immunotherapy effects.

CN119055755APending Publication Date: 2024-12-03陶惠人 +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311836941.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-12-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing osteoporosis treatment drugs have side effects and high cost problems, especially anti-RANKL monoclonal antibodies may lead to bone loss and multiple vertebral fractures after withdrawal, and the long-term prevention and treatment effect is not good.

Method used

An osteoporosis vaccine was designed, using the transmembrane domain DTT 203-378aa peptide of diphtheria toxin as an immune scaffold, connecting the hRANKL 220-245aa peptide, expressed and purified by genetic engineering methods, and used to induce specificity in vivo production. anti-RANKL antibody blocks RANKL signaling pathways and prevents or treats osteoporosis.

Benefits of technology

The vaccine can effectively prevent or treat osteoporosis, avoid bone loss after the removal of anti-RANKL monoclonal antibodies, and is at a low cost, providing a gentle and lasting treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055755A_ABST
    Figure CN119055755A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biomedical engineering, in particular to an osteoporosis vaccine and a preparation method and application thereof. The amino acid sequence of the osteoporosis vaccine provided by the invention comprises a transmembrane domain DTT 203-378aa peptide fragment of diphtheria toxin and at least one hRANKL 220-245aa peptide fragment of the diphtheria toxin. According to the application, a transmembrane domain DTT 203-378aa peptide fragment of diphtheria toxin is taken as an immune scaffold and is connected with an hRANKL 220-245aa peptide fragment capable of being combined with Denosumab, and finally, experiments find that the osteoporosis vaccine can generate a specific anti-RANKL antibody, so that the osteoporosis vaccine can be used for well preventing or treating osteoporosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application belongs to the field of biomedical engineering technology, and in particular relates to an osteoporosis vaccine and a preparation method and application thereof. Background Art

[0002] Osteoporosis (OP) and its complications such as fractures have become a serious health problem. Currently, the drugs for the treatment of osteoporosis mainly include calcium, vitamin D3, bisphosphonates, teriparatide, etc., and each drug has its limitations. For example, long-term use of bisphosphonates can cause side effects such as mandibular osteonecrosis and esophagitis; and teriparatide is contraindicated in patients with bone metastasis or malignant bone tumors. Therefore, there is an urgent need to explore more effective, safe and economical therapeutic drugs.

[0003] The strength and integrity of bones depend on the dynamic balance between osteoclast bone resorption and osteoblast bone formation. Excessive enhancement of osteoclast activity is the main pathological mechanism leading to osteoporosis. Members of the triad receptor superfamily: osteoprotegerin (OPG) / receptor activator of nuclear factor-κB ligand (RANKL) / receptor activator of nuclear factor-κB (RANK), namely the OPG / RANKL / RANK signaling pathway is the key signaling pathway for the body to control the differentiation, maturation and function of osteoclasts. By blocking this key signaling pathway, the differentiation and osteoclast activity of osteoclasts can be inhibited, thereby achieving a therapeutic effect on bone resorption diseases.

[0004] For example, Denosumab, as an anti-RANKL humanized monoclonal antibody, can specifically block the binding of RANKL to its receptor, effectively block the release of osteoclast differentiation signals from the upstream of the signal transduction pathway, and has significant therapeutic effects on bone resorption diseases, especially osteoporosis, bone metastasis of solid tumors (preventing patients from experiencing bone-related events) and giant cell tumors of bone. The successful application of anti-RANKL humanized monoclonal antibodies has opened the precedent for immunotherapy of bone resorption diseases such as osteoporosis. However, for the long-term prevention and treatment of chronic diseases, monoclonal antibodies significantly inhibit osteoclast function in the short term, which may cause a large disturbance to bone homeostasis. Therefore, once Denosumab is withdrawn, it may cause a large number of accumulated osteoclast precursor cells / bone morphological cells to re-form osteoclasts, resulting in a rapid loss of increased bone mass, accompanied by the occurrence of multiple vertebral fractures, etc. In addition, the high cost of antibodies also limits their application. Therefore, for the long-term prevention and treatment of chronic bone loss diseases such as osteoporosis, exploring more gentle, lasting, precise and effective treatment approaches may bring positive clinical effects. Among them, vaccine therapy may be an effective and economical strategy. Summary of the invention

[0005] The purpose of this application is to provide an osteoporosis vaccine and its preparation method and application, aiming to solve the technical problem of how to achieve osteoporosis immunotherapy in a longer-term, milder and lower-cost manner.

[0006] In order to achieve the above application purpose, the technical solution adopted in this application is as follows:

[0007] In a first aspect, the present application provides an osteoporosis vaccine, the amino acid sequence of which includes a transmembrane domain DTT 203-378aa peptide segment of diphtheria toxin and at least one hRANKL 220-245aa peptide segment.

[0008] In some embodiments, the osteoporosis vaccine comprises the transmembrane domain DTT 203-378aa peptide segment and 1-5 hRANKL 220-245aa peptide segments connected in sequence.

[0009] In some embodiments, the transmembrane domain DTT 203-378aa peptide segment and the hRANKL 220-245aa peptide segment, as well as adjacent hRANKL 220-245aa peptide segments are connected by (GGGGS)2.

[0010] In some embodiments, the amino acid sequence of the osteoporosis vaccine is shown as SEQ ID No.1.

[0011] In a second aspect, the present application provides a nucleic acid molecule, which expresses the osteoporosis vaccine provided in the first aspect of the present application.

[0012] In some embodiments, the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID No.2.

[0013] In a third aspect, the present application provides an expression vector, wherein the expression vector contains the nucleic acid molecule provided in the second aspect of the present application.

[0014] In some embodiments, the expression vector is obtained by inserting the nucleic acid molecule into the cloning vector pGEX-6P-1.

[0015] In a fourth aspect, the present application provides a method for preparing an osteoporosis vaccine, comprising the following steps:

[0016] Constructing the expression vector provided in the third aspect of the present application;

[0017] The expression vector is transferred into Escherichia coli for expression and purification to obtain the osteoporosis vaccine.

[0018] The osteoporosis vaccine provided in the first aspect of the present application uses the transmembrane domain DTT 203-378aa peptide of diphtheria toxin as an immune scaffold, which is connected to the hRANKL 220-245aa peptide that can bind to Denosumab. Finally, through experiments, it was found that such an osteoporosis vaccine can produce specific anti-RANKL antibodies when injected into mice for immunization. Therefore, such an osteoporosis vaccine can effectively prevent or treat osteoporosis.

[0019] The nucleic acid molecule provided in the second aspect of the present application can express the osteoporosis vaccine unique to the present application, that is, it can be used to express an osteoporosis vaccine that can produce specific anti-RANKL antibodies through in vivo immunity, and therefore has a good application prospect.

[0020] The expression vector provided in the third aspect of the present application contains a nucleic acid molecule that can express the osteoporosis vaccine unique to the present application, so such an expression vector can be used to prepare the osteoporosis vaccine through genetic engineering vector expression.

[0021] The fourth aspect of the present application provides a method for preparing an osteoporosis vaccine, which comprises transferring the unique expression vector of the present application into Escherichia coli for expression and purification, and adopting a mature genetic engineering method to prepare the target fusion protein, thereby enabling large-scale production of the osteoporosis vaccine of the present application.

[0022] The application provided in the fifth aspect of the present application is based on the characteristics of the hRANKL 220-245aa peptide segment and can therefore be used to prepare an osteoporosis vaccine. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0024] Figure 1 is a hRANKL T / B cell epitope map provided in the examples of the present application, wherein A is a CTL epitope (CTLepitopes) number prediction map, B is a CTL epitope (CTL epitopes) % rank prediction map, C is a HTL epitope (HTLepitopes) number prediction map, D is a HTL epitope (HTL epitopes) % rank prediction map, and E is a linear B cell epitope prediction map;

[0025] Figure 2 : is a result diagram of hRANKL and Denusmab binding site screening provided in the examples of the present application; wherein A is the position distinction of hRANKL1 (210-235aa), hRANKL2 (195-220aa) and hRANKL3 (220-245aa), B is an absorbance detection diagram after binding with Denusmab, and C is a result diagram of hRANKL3 (220-245aa) inducing osteoclast differentiation;

[0026] Figure 3 : is a vaccine design diagram provided in the embodiment of the present application, wherein A is a vaccine design schematic diagram, B is a vaccine molecular dynamics simulation diagram, and C is the immune simulation effect of vaccine DR3 and DR5;

[0027] Figure 4 This is a purification diagram of the vaccine DR3 protein expression provided in the examples of the present application;

[0028] Figure 5 It is a graph of specific antibodies produced by the immunization of the vaccine DR3 provided in the examples of the present application, wherein A is a graph of specific anti-RANKL antibody detection, and B is a graph of immune serum inhibiting osteoclasts;

[0029] Figure 6 This is a graph showing the protection of bone loss by the vaccine DR3 provided in the examples of the present application, wherein A is a graph showing the bone density results, and B is a graph showing the trabecular number results. DETAILED DESCRIPTION

[0030] In order to make the technical problems, technical solutions and beneficial effects to be solved by the present application more clearly understood, the present application is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present application and are not used to limit the present application.

[0031] In this application, the term "and / or" describes the association relationship of associated objects, indicating that there may be three relationships. For example, A and / or B can mean: A exists alone, A and B exist at the same time, and B exists alone. A and B can be singular or plural. The character " / " generally indicates that the associated objects are in an "or" relationship.

[0032] In the present application, "at least one" means one or more, "more than one" means two or more. "At least one of the following" or similar expressions refers to any combination of these items, including any combination of single or plural items.

[0033] It should be understood that in the various embodiments of the present application, the size of the serial numbers of the above-mentioned processes does not mean the order of execution, some or all of the steps can be executed in parallel or sequentially, and the execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of the present application.

[0034] The terms used in the embodiments of the present application are only for the purpose of describing specific embodiments, and are not intended to limit the present application. The singular forms "a", "said" and "the" used in the embodiments of the present application and the appended claims are also intended to include plural forms, unless the context clearly indicates other meanings.

[0035] The weight of the relevant components mentioned in the embodiment description of the present application can not only refer to the specific content of each component, but also represent the proportional relationship between the weights of the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the embodiment description of the present application, it is within the scope disclosed in the embodiment description of the present application. Specifically, the mass described in the embodiment description of the present application can be a mass unit known in the chemical industry such as μg, mg, g, kg, etc.

[0036] The terms "first" and "second" are used only for descriptive purposes to distinguish objects such as substances from each other, and should not be understood as indicating or implying relative importance or implicitly indicating the number of indicated technical features. For example, without departing from the scope of the embodiments of the present application, the first XX may also be referred to as the second XX, and similarly, the second XX may also be referred to as the first XX. Thus, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features.

[0037] Given that anti-RANKL humanized monoclonal antibodies have a strong inhibitory effect that leads to rebound bone loss after drug withdrawal and their high cost, it is particularly important to explore more gentle, durable, precise and effective long-term treatment approaches. Therefore, developing a vaccine against autologous RANKL protein to induce the body to produce specific anti-RANKL neutralizing antibodies is a more effective and cost-effective strategy.

[0038] Denosumab, as an anti-RANKL humanized monoclonal antibody, has high affinity and specificity for RANKL and has been successfully used in the treatment of bone resorption diseases, especially osteoporosis, bone metastasis of solid tumors, and giant cell tumors of bone. This is likely to indicate that the site where Denosumab binds to RANKL is the potent site where RANKL exerts its biological function. Therefore, as long as the specific location of the site is clear, a new vaccine that produces neutralizing antibodies similar to Denosumab against the specific binding site of RANKL can be designed based on the idea of ​​reverse vaccine design, thereby achieving targeted and precise vaccine design.

[0039] In the previous series of RANKL recombinant vaccines modified with non-natural amino acids constructed by the applicant, p-Y234 and p-Y240 vaccines had the best therapeutic effect on osteoporosis and rheumatoid arthritis mice, and the sites of non-natural amino acid modification of p-Y234 and p-Y240 vaccines happened to be located in the specific epitope of RANKL, suggesting that this peptide segment is very likely to be the key target for designing RANKL epitope peptide vaccines. However, the non-natural amino acid insertion method for constructing vaccines has its own limitations. First, there is uncertainty between the selection of non-natural amino acid insertion sites and the effect of vaccines on breaking the immune tolerance of self-proteins, and the efficiency of non-natural amino acid mutation systems is low; secondly, the binding of endogenous antibodies produced by the body induced by non-natural amino acid insertion vaccines and target proteins is random, and it is impossible to effectively induce the body to produce endogenous antibodies similar to Denosumab; finally, the non-natural amino acid insertion vaccine itself has a complete RANKL extracellular segment structure, which cannot eliminate the stimulating effect of the vaccine itself on osteoclast function.

[0040] Therefore, immuno scaffolding is a new design idea. Through analysis, this application intends to select the transmembrane domain of diphtheria toxin (Diphtheria Toxin-T domain, DT-T) as the immuno scaffold. Because DT-T has the following significant advantages: (1) DT-T has the immunogenicity of diphtheria toxin without biological toxicity; (2) DT-T is rich in universal CD4+Cell Epitope, which can be recognized by almost 98% of helper T receptor cells, that is, it can activate the vast majority of helper T cells. The activation of helper T cells synergistically promotes the activation and proliferation of B cells, as well as initiates B cell somatic hypermutation and antibody rearrangement, and the latter plays a vital role in antibody maturation and improving the affinity for antigens.

[0041] In a first aspect, an embodiment of the present application provides an osteoporosis vaccine, the amino acid sequence of which includes a transmembrane domain DTT 203-378aa peptide segment of diphtheria toxin and at least one hRANKL 220-245aa peptide segment.

[0042] The osteoporosis vaccine of the embodiment of the present application is a vaccine targeting autologous RANKL protein, which uses the transmembrane domain DTT 203-378aa peptide of diphtheria toxin as an immune scaffold, and connects it to the hRANKL220-245aa peptide that can bind to Denosumab. Finally, through experiments, it was found that such an osteoporosis vaccine can produce specific anti-RANKL antibodies when injected into mice for immunization. Therefore, such an osteoporosis vaccine can effectively prevent or treat osteoporosis.

[0043] It should be noted that the transmembrane domain DTT 203-378aa peptide refers to the polypeptide fragment of the 203-378 amino acids (a total of 176 amino acids) of the transmembrane domain DTT of diphtheria toxin; the hRANKL 220-245aa peptide refers to the polypeptide fragment of the 220-245 amino acids (a total of 26 amino acids) of the nuclear factor-κB receptor activator ligand.

[0044] In some embodiments, the osteoporosis vaccine comprises a transmembrane domain DTT 203-378aa peptide segment and 1-5 hRANKL 220-245aa peptide segments connected in sequence. That is, from the N-terminus to the C-terminus, the transmembrane domain DTT 203-378aa and 1-5 hRANKL 220-245aa peptide segments are sequentially connected. Such an osteoporosis vaccine can be well immunized in vivo to produce specific anti-RANKL antibodies.

[0045] In some embodiments, the transmembrane domain DTT 203-378aa peptide segment and the hRANKL 220-245aa peptide segment, as well as adjacent hRANKL 220-245aa peptide segments, are connected by (GGGGS) 2. This can give each peptide segment in the osteoporosis vaccine a certain amount of wiggle room while ensuring its antigenicity.

[0046] In some embodiments, the amino acid sequence of the osteoporosis vaccine is as follows:

[0047] SEQ ID No.1 (i.e., the amino acid sequence of the DR3 vaccine in the embodiment):

[0048] MYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAGANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADG AVHHNTEEIVAQSIALSSLMVAQAIPLVGELVDIGGGGSGGGGSICFRHHETSGDLATEYLQLMVYVTKTGGGGSGGGGSICFRHHETSGDLATEYLQLMVYVTKTGGGGSGGGGSICFRHHETSGDLATEYLQLMVYVTKT.

[0049] In a second aspect, the present invention provides a nucleic acid molecule that expresses the osteoporosis vaccine provided in the present invention. The nucleic acid molecule can be used to express an osteoporosis vaccine that can produce specific anti-RANKL antibodies in vivo, and thus has a good application prospect.

[0050] In some embodiments, the nucleotide sequence of the nucleic acid molecule is as shown in SEQ ID No. 2 below, that is, the osteoporosis vaccine shown in SEQ ID No. 1 is expressed.

[0051] SEQ ID No.2:

[0052] .

[0053] In a third aspect, the present application provides an expression vector, which contains the above-mentioned nucleic acid molecule provided in the present application. The expression vector contains a nucleic acid molecule that can express the osteoporosis vaccine specific to the present application, so such an expression vector can prepare the osteoporosis vaccine by a genetic engineering vector expression method.

[0054] In some embodiments, the expression vector is obtained by inserting the nucleic acid molecule into the cloning vector pGEX-6P-1. Specifically, the cloning site of the cloning vector pGEX-6P-1 is BamHI--XhoI.

[0055] In a fourth aspect, the present application provides a method for preparing an osteoporosis vaccine, comprising the following steps:

[0056] S01: construct the above expression vector provided in the examples of this application;

[0057] S02: The above expression vector is transferred into Escherichia coli for expression and purification to obtain an osteoporosis vaccine.

[0058] The present embodiment of the application can adopt a mature genetic engineering method for preparing the target fusion protein, so that the osteoporosis vaccine designed in the present embodiment of the application can be produced on a large scale.

[0059] In a fifth aspect, the embodiments of the present application also provide a use of the hRANKL 220-245aa peptide segment in the preparation of an osteoporosis vaccine based on the characteristics of the hRANKL 220-245aa peptide segment.

[0060] The following describes the invention in conjunction with specific embodiments.

[0061] Example 1

[0062] 1. Screening of human hRANKL specific epitope peptides

[0063] The present application example determined through bioinformatics analysis that the appropriate extracellular domain (ECO) of hRANKL has a T / B cell region, and screened out specific binding short peptides using Denosumab, and analyzed the possibility of the short peptides becoming a vaccine through osteoclast differentiation experiments.

[0064] 1.1 Analysis of T cell and B cell epitopes in the extracellular region of hRANKL (159-317aa). NetMHCpan-4.1 predicted MHC class I restricted epitopes: the peptide length of cytotoxic T cell (CTL) epitopes was 9mers, and was considered as strong binding (SB) and weak binding (WB) epitopes according to % rank <0.5% and <2%, respectively. The NetMHCIIpan 4.0 online server was used to detect helper T lymphocyte (HTL) epitopes. The peptide length of HTL epitopes was 15mers. HTL epitopes were defined as SB epitopes according to % rank <1%, and as WB epitopes according to % rank <5%. Linear B cell epitopes (16mers) were predicted by BepiPred 3.0 (threshold of 0.15). Based on the above analysis results and the binding region of RANK, it was roughly confirmed that the RANKL 195-245aa region was used to screen the binding epitope of Denosumab and was divided into hRANKL1 (210-235aa), hRANKL2 (195-220aa) and hRANKL3 (220-245aa).

[0065] The final result is Figure 1 As shown in Figure 2, hRANKL 159-317aa has 33 CTL epitopes and 30 HTL epitopes, among which Figure 1 A and B show that the CTL epitopes are located at 206-247aa (there are 13 CTL epitopes here, including 9 weak binders and 4 strong binders) and 248-282aa (there are 9 CTL epitopes here, including 4 weak binders and 5 strong binders); Figure 1 C and D show that the HTL epitopes are mainly located at 207-258aa (there are 14 CTL epitopes here, including 12 weak binders and 2 strong binders). Figure 1 E showed that there were three linear B-cell epitopes located at 224-239aa, 245-255aa, and 258-273aa. Therefore, comprehensive analysis showed that the T-cell and B-cell epitopes of the hRANKL extracellular segment were mainly located at residues 206-255aa, while the RANKL-RANK binding site was mainly located in the binding pocket composed of K181, R223, D Q237, and T241. Finally, based on the T-cell and B-cell epitopes and the RANKL-RANK binding site, we selected hRANKL 195-245aa for screening RANKL epitopes that specifically bind to DMAB.

[0066] 1.2 Dilute mouse RANKL (mRANKL), hRANKL, hRANKL 210-235aa, hRANKL 195-220aa, and hRANKL 220-245aa to 2 μg / ml with coating buffer (Abcam), and use them as antigens to coat 96-well plates with 100 μl / well at 4°C overnight. Discard the coating buffer, wash 4 times with washing solution, and add blocking buffer (Abcam) (100 μl / well). Incubate at 37°C for 2 hours, and then rinse 4 times. After washing, Denosumab powder (Glpbio) was prepared with phosphate buffer solution (PBS) to 100 ng / ml, added to the plate at 100 μl / well, incubated at 37°C for 2 h, then washed 4 times, horseradish peroxidase (HRP)-labeled rabbit anti-human IgG polyclonal antibody (with antibody dilution volume dilution ratio of 1:10 000) was added to the plate, incubated at 37°C for 2 h, and then 100 μl / well of 3,3',5,5'-tetramethylbenzidine (TMB) (Abcam) was added, incubated at 37°C for 20 min, and the reaction was stopped with stop solution (Abcam). Finally, the absorbance was measured at 450 nm.

[0067] In addition, the femur of C57BL / 6J mice was taken, the epiphyses at both ends were cut off, and the femur was rinsed with α-MEM complete medium (containing 10% fetal bovine serum and 1% penicillin-streptomycin) using a 1ml syringe to collect bone marrow. According to the instructions of the mouse bone marrow mononuclear cell isolation kit (Solebo), bone marrow mononuclear cells were extracted. The cells were inoculated in a 100mm culture dish and cultured overnight at 5% CO2 and 37°C. Non-adherent cells were collected and 8×10 cells were added to each well. 4 The cells were seeded in 96-well plates and cultured for 48 h with the addition of M-CSF at a final concentration of 50 ng / ml, followed by the addition of α-MEM complete medium containing 100 ng / ml RANKL220-245aa or RANKL for a further 4 days.

[0068] The final result is Figure 2 As shown in the figure, RANKL220-245aa can bind to Denosumab. At the same time, osteoclast culture experiments confirmed that hRANKL220-245aa could not induce osteoclastogenesis.

[0069] 2. Vaccine design and tertiary structure prediction

[0070] The transmembrane domain of diphtheria toxin (DTT, 203-378aa) was used as an immune scaffold, and one RANKL220-245aa (expressed by DR3), three RANKL220-245aa (expressed by DR5), and five RANKL220-245aa (expressed by DR7) epitope peptides were directly connected to the C-terminus of DTT using Linker (GGGGSGGGGS) to form a fusion antigen protein. Figure 3 As shown in A, DR0 indicates that DTT is not connected to RANKL220-245aa, DR1 indicates that DTT is connected to one RANKL220-245aa, DR3 indicates that DTT is connected to three RANKL220-245aa, and DR5 indicates that DTT is connected to five RANKL220-245aa; the two adjacent RANKL220-245aa in the above DR1, DR3 and DR5 are also connected through Linker (GGGGSGGGGS).

[0071] Furthermore, the structure of the designed vaccine was predicted by the AlphaFold2 online server (https: / / colab.research.google.com / github / sokrypton / ColabFold / blob / main / AlphaFold2.ipynb). The stability of the vaccine was analyzed by GROMACS, and OPLS (Optimized Potential for Liquid Simulation) was selected as the analysis force field. The vaccine was set to be contained in a cubic box, 2nm away from the boundary, and spc216.gro was selected as the filling solvent. The system was made electrically neutral by adding solvent molecules and ions. Energy minimization was then performed to obtain the final structure of energy minimization (EM). The temperature of the protein was stabilized using the NVT isothermal-isochroic ensemble equilibrium of 100ps. For the equilibrium structure, the MD simulation was run at a speed of 1ns, a step size of 2fs, and a step number of 500000. The stability of the designed vaccine was evaluated by comparing the minimum energy RMSD. Whether the designed vaccines have different immune induction was analyzed by immune simulation (same method).

[0072] The final result is Figure 3 As shown in Figure 5A-C, by comparison, DR3 and DR5 can well maintain the natural spatial structure of hRANKL220-245, while DR1 does not. Therefore, we selected DR3 and DR5 as candidate vaccines. Further analysis found that there was not much difference between DR3 and DR5 in terms of stability and the time and titer of antibodies induced by immune stimulation. Therefore, under the premise that there was no difference in the stability of vaccine proteins and no significant difference in immune effects, considering the difficulty of actual vaccine preparation in the future and the time-economic benefits, in this study we finally selected DR3 as a candidate vaccine for subsequent analysis.

[0073] 3. Evaluation of the allergenicity, antigenicity and physicochemical properties of vaccine DR3

[0074] AllerTOP v.2.0 predicts that vaccine DR3 is a non-allergen; VaxiJen v2.0 and ANTIGENPro calculate the vaccine DR3 antigenicity scores to be 0.9767 and 0.9260, respectively. In addition, the solubility of vaccine protein is also a key indicator of the vaccine. The solubility of vaccine DR3 is scored as 0.9251 and 0.604 in SolPro and Protein-Sol, respectively, indicating that vaccine DR3 also has good solubility. The physical and chemical properties of the vaccine protein were analyzed by ExPasy's ProtParam. Vaccine DR3 contains 284 amino acids (as shown in SEQ ID No.1), with a molecular weight of approximately 30 kDa, including 32 negatively charged residues (Asp+Glu) and 21 positively charged residues (Arg+Lys). The theoretical protein isoelectric point (pI) value is 5.44, and the molecular chemical formula is: C 1305 H 2069 N 361 O 424 S 13 The estimated half-life in mammalian reticulocytes in vitro is 30 hours, the estimated half-life in yeast is about more than 20 hours, and more than 10 hours in E. coli. The aliphatic index of vaccine DR3 is 81.73, indicating high temperature resistance. GRAVY is -0.157, indicating that the vaccine is hydrophilic.

[0075] 4. Vaccine DR3 expression

[0076] This example uses a common genetic engineering method to prepare the target fusion protein, and obtains the analytical vaccine DR3 by expressing it in E. coli. The expression and purification are entrusted to General Biotech Co., Ltd. The cloning vector is pGEX-6P-1, and the cloning site is BamHI--XhoI.

[0077] The final purified expression results are shown in Figure 4 .

[0078] 5. Vaccine DR3 Immunization

[0079] Ten 7-week-old B6-hRANKL mice (purchased from Jicui Pharmaceutical) were divided into two groups: (1) DR0 group: a control group immunized with DR0 (DTT was not linked to RANKL220-245aa); (2) DR3 group: a group immunized with the target vaccine DR3. The immune protein dose was 100 μg / mouse, and the injection method was subcutaneous injection into the lower limb of the mouse. Each immunization was 2 weeks apart, for a total of 3 immunizations. Two weeks after the last immunization, the mouse serum and femur samples were collected for analysis.

[0080] 6. Detection of antibody titer in sera of immune mice

[0081] hRANKL was diluted to 2 μg / ml with coating buffer (Abcam), and the antigen was coated on a high-absorption 96-well plate at 100 μl / well at 4°C overnight. The coating buffer was discarded, washed 4 times with washing solution, and blocking buffer (Abcam) (100 μl / well) was added. After incubation at 37°C for 2 hours, rinsed 4 times. After washing, mouse serum diluted 100 times was added, incubated at 37°C for 2 hours, then washed 4 times, HRP-labeled goat anti-mouse IgG polyclonal antibody (with a volume dilution ratio of 1:10000 to antibody diluent) was added to the plate, incubated at 37°C for 2 hours, and then 100 μl / well of TMB (Abcam) was added. After incubation at 37°C for 20 minutes, the reaction was stopped with stop solution (Abcam). Finally, the absorbance was measured at 450 nm.

[0082] The osteoclast culture method was the same as the experimental steps in "1.2" above, and α-MEM complete medium with or without immune serum was added and cultured for 4 days.

[0083] The results are as follows Figure 5 The DR3 group immunized mice can produce specific anti-RANKL antibodies, that is, DR3 vaccine immunization produces specific antibodies. In addition, immune serum can effectively inhibit the differentiation and maturation of osteoclasts in vitro.

[0084] 7. Micro-CT analysis

[0085] After removing the soft tissue of the above immunized mice, the trabecular bone of the distal femur was evaluated using a Micro-CT device. The scanning parameters were: voltage 55kV, current 145μA, power 8W, and resolution 10.4μm. The structural parameters of the region of interest (ROI) 2.4mm away from the distal femoral growth plate were analyzed using the CTAN program (Brukermicro-CT, Kontich, Belgium), including bone density (BMD), bone volume / tissue volume (BV / TV), trabecular number (Tb.N), and trabecular separation (Tb.Sp).

[0086] The results are as follows Figure 6 As shown, the bone mineral density (BMD) of the DR3 group in A was significantly higher than that of the DR0 group, and the trabecular number (Tb.N) of the DR3 group in B was significantly higher than that of the DR0 group.

[0087] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present application should be included in the protection scope of the present application.

Claims

1. An osteoporosis vaccine, characterized in that: The amino acid sequence of the osteoporosis vaccine includes a transmembrane domain DTT 203-378aa peptide segment of diphtheria toxin and at least one hRANKL 220-245aa peptide segment.

2. The osteoporosis vaccine according to claim 1, characterized in that The osteoporosis vaccine comprises the transmembrane domain DTT 203-378aa peptide segment and 1-5 hRANKL 220-245aa peptide segments which are sequentially connected.

3. The osteoporosis vaccine according to claim 2, characterized in that The transmembrane domain DTT 203-378aa peptide segment and the hRANKL 220-245aa peptide segment, as well as adjacent hRANKL 220-245aa peptide segments, are connected by (GGGGS)2.

4. The osteoporosis vaccine according to any one of claims 1 to 3, characterized in that The amino acid sequence of the osteoporosis vaccine is shown in SEQ ID No.

1.

5. A nucleic acid molecule, characterized in that The nucleic acid molecule expresses the osteoporosis vaccine according to any one of claims 1-4.

6. The nucleic acid molecule according to claim 5, characterized in that The nucleotide sequence of the nucleic acid molecule is shown as SEQ ID No.

2.

7. An expression vector, characterized in that: The expression vector contains the nucleic acid molecule according to claim 5 or 6.

8. The expression vector according to claim 7, characterized in that The expression vector is obtained by inserting the nucleic acid molecule into the cloning vector pGEX-6P-1.

9. A method for preparing an osteoporosis vaccine, characterized in that: include: Constructing the expression vector according to claim 7 or 8; The expression vector is transferred into Escherichia coli for expression and purification to obtain the osteoporosis vaccine.

10. Application of hRANKL 220-245aa peptide fragment in the preparation of osteoporosis vaccine.